Biotech Values

[cooldrinkh2o]

POTP:

The company seems to be pursuing a registrational strategy of comparing Talabostat plus Taxotere to Taxotere alone ( as well as Talabostat plus Alimta vs. Alimta alone in third line). Since there is no prior head to head data to rely upon, we are using the next best thing: comparing two different trials in similiar patient populations, making adjustments for the differences and trying to get a sense of the possible outcomes in the pivotal trial.